BRPI0412860A - derivados de 2-[4-(2-hidroximetil-fenilamino)-piperidin-1-il]-n-(9h-ca rbazol-3-il)- acetamida e compostos relacionados como ligantes do neuropeptìdeo y5 (npy5) para o tratamento de obesidade - Google Patents

derivados de 2-[4-(2-hidroximetil-fenilamino)-piperidin-1-il]-n-(9h-ca rbazol-3-il)- acetamida e compostos relacionados como ligantes do neuropeptìdeo y5 (npy5) para o tratamento de obesidade

Info

Publication number
BRPI0412860A
BRPI0412860A BRPI0412860-5A BRPI0412860A BRPI0412860A BR PI0412860 A BRPI0412860 A BR PI0412860A BR PI0412860 A BRPI0412860 A BR PI0412860A BR PI0412860 A BRPI0412860 A BR PI0412860A
Authority
BR
Brazil
Prior art keywords
npy5
piperidin
obesity
hydroxymethyl
treatment
Prior art date
Application number
BRPI0412860-5A
Other languages
English (en)
Inventor
Antoni Torrens Jover
Josep Mas Prio
Alberto Dordal Zueras
Maria Angeles Fisas Escasany
Helmut Heinrich Buschmann
Original Assignee
Esteve Labor Dr
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr
Publication of BRPI0412860A publication Critical patent/BRPI0412860A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C07D211/58—Nitrogen atoms attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Manufacturing & Machinery (AREA)
  • Pain & Pain Management (AREA)
  • Ceramic Engineering (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Structural Engineering (AREA)
  • Materials Engineering (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

"DERIVADOS DE 2-¢4-(2-HIDROXIMETIL-FENILAMINO)-PIPERIDIN-1IL!-N-(9H-CAR BAZOL-3-IL)-ACETAMIDA E COMPOSTOS RELACIONADOS COMO LIGANTES DO NEUROPEPTìDEO Y5 (NPY5) PARA O TRATAMENTO DE OBESIDADE". A presente invenção relaciona-se aos compostos de piperidina 1,4-dissubstituída de fórmula geral (I), a métodos para sua preparação, a medicamentos compreendendo estes compostos assim como a seu uso para a preparação de um medicamento para o tratamento de humanos ou animais. Os substituintes são conforme definidos na presente reivindicação 1.
BRPI0412860-5A 2003-07-30 2004-07-29 derivados de 2-[4-(2-hidroximetil-fenilamino)-piperidin-1-il]-n-(9h-ca rbazol-3-il)- acetamida e compostos relacionados como ligantes do neuropeptìdeo y5 (npy5) para o tratamento de obesidade BRPI0412860A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200301813A ES2222833B1 (es) 2003-07-30 2003-07-30 Compuestos piperidinicos 1,4-disustituidos, su preparacion y su uso como medicamentos.
PCT/EP2004/008517 WO2005013990A1 (en) 2003-07-30 2004-07-29 2-`4-(hydroxymethyl-phenylamino) -piperidine-1-yl!-n- (9h-carbazol-3-yl) - acetamine derivatives and related compounds as neuropeptide y5 (npy5) ligands for the treatment of obesity

Publications (1)

Publication Number Publication Date
BRPI0412860A true BRPI0412860A (pt) 2006-10-03

Family

ID=34130546

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0413091-0A BRPI0413091A (pt) 2003-07-30 2004-07-29 compostos de piperidina 1,4-di-substituìdo, seus métodos de preparação, seus medicamentos e usos
BRPI0412860-5A BRPI0412860A (pt) 2003-07-30 2004-07-29 derivados de 2-[4-(2-hidroximetil-fenilamino)-piperidin-1-il]-n-(9h-ca rbazol-3-il)- acetamida e compostos relacionados como ligantes do neuropeptìdeo y5 (npy5) para o tratamento de obesidade

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0413091-0A BRPI0413091A (pt) 2003-07-30 2004-07-29 compostos de piperidina 1,4-di-substituìdo, seus métodos de preparação, seus medicamentos e usos

Country Status (19)

Country Link
US (4) US7888510B2 (pt)
EP (2) EP1651220B1 (pt)
JP (2) JP2007500169A (pt)
CN (2) CN1832745A (pt)
AR (1) AR045154A1 (pt)
AT (2) ATE348615T1 (pt)
AU (2) AU2004262482A1 (pt)
BR (2) BRPI0413091A (pt)
CA (2) CA2534096A1 (pt)
DE (2) DE602004003831T2 (pt)
ES (3) ES2222833B1 (pt)
MX (2) MXPA06001140A (pt)
MY (1) MY136965A (pt)
NO (2) NO20060553L (pt)
PE (1) PE20050332A1 (pt)
PT (2) PT1651220E (pt)
RU (2) RU2006105711A (pt)
TW (1) TW200510379A (pt)
WO (2) WO2005013990A1 (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9560804B1 (en) 2010-12-15 2017-02-07 Marion Calmer Stalk roll with flutes defining a recess
ES2222833B1 (es) * 2003-07-30 2006-03-01 Laboratorios Del Dr. Esteve, S.A. Compuestos piperidinicos 1,4-disustituidos, su preparacion y su uso como medicamentos.
EP1918281A1 (en) * 2006-11-02 2008-05-07 Laboratorios del Dr. Esteve S.A. Phenylamino-substituted piperidine compounds, their preparation and use as medicaments
EP2129219A4 (en) 2007-02-16 2012-08-29 Synta Pharmaceuticals Corp SUBSTITUTED FUSED CYCLE COMPOUNDS USED IN CASES OF INFLAMMATION OR IMMUNE DISORDERS
CN102272120B (zh) * 2008-11-07 2013-12-25 H.隆德贝克有限公司 生物活性酰胺
AU2021324684A1 (en) * 2020-08-11 2023-04-20 Board Of Trustees Of Michigan State University Proteasome enhancers and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7692996A (en) 1995-12-01 1997-06-27 Ciba-Geigy Ag Receptor antagonists
AU1328197A (en) 1995-12-01 1997-06-19 Synaptic Pharmaceutical Corporation Aryl sulfonamide and sulfamide derivatives and uses thereof
US6043246A (en) 1996-12-03 2000-03-28 Banyu Pharmaceutical Co., Ltd. Urea derivatives
US6048900A (en) * 1998-02-13 2000-04-11 Bayer Corporation Amide derivatives and methods for using the same as selective neuropeptide Y receptor antagonists
WO1998035957A1 (en) * 1997-02-14 1998-08-20 Bayer Corporation Amide derivatives as selective neuropeptide y receptor antagonists
AU6309698A (en) 1997-03-12 1998-09-29 Banyu Pharmaceutical Co., Ltd. Drugs containing aminopyridine derivatives as the active ingredient
US7534857B2 (en) * 1997-12-19 2009-05-19 Centegen, Inc. Methods and compositions for the treatment and prevention of staphylococcal infections
US6187777B1 (en) 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
NZ510988A (en) 1998-10-07 2005-01-28 Ortho Mcneil Pharm Inc N-aralkylaminotetralins useful as ligands for the neuropeptide Y5 receptor
WO2001007409A1 (en) * 1999-07-23 2001-02-01 Astrazeneca Uk Limited Carbazole derivatives and their use as neuropeptide y5 receptor ligands
US6399631B1 (en) * 1999-07-23 2002-06-04 Pfizer Inc. Carbazole neuropeptide Y5 antagonists
HUP0202143A3 (en) * 1999-07-28 2003-12-29 Ortho Mcneil Pharm Inc Amine and amide derivatives as ligands for the neuropeptide y y5 receptor pharmaceutical compositions containing them and their use
WO2001013917A1 (en) 1999-08-26 2001-03-01 Bristol-Myers Squibb Company Npy antagonists: spiroisoquinolinone derivatives
KR100890676B1 (ko) * 2001-07-24 2009-03-26 리히데 게데온 베기에스제티 기아르 알티 신규한 카르복시산 아미드 화합물
US7067549B2 (en) * 2001-12-31 2006-06-27 Actelion Pharmaceuticals Ag Pyrrolidone carboxamides
ES2193875B2 (es) * 2002-04-09 2005-03-01 Laboratorios Del Dr. Esteve, S.A. Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos.
ES2228267B1 (es) * 2003-07-30 2006-07-01 Laboratorios Del Dr. Esteve, S.A. Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6.
ES2222833B1 (es) * 2003-07-30 2006-03-01 Laboratorios Del Dr. Esteve, S.A. Compuestos piperidinicos 1,4-disustituidos, su preparacion y su uso como medicamentos.

Also Published As

Publication number Publication date
DE602004003831T2 (de) 2007-10-25
CA2534096A1 (en) 2005-02-17
US7888510B2 (en) 2011-02-15
US20100280072A1 (en) 2010-11-04
ES2279419T3 (es) 2007-08-16
BRPI0413091A (pt) 2006-10-03
MXPA06001226A (es) 2006-05-15
AR045154A1 (es) 2005-10-19
EP1648458B1 (en) 2006-12-20
WO2005013988A8 (en) 2006-11-09
EP1651220A1 (en) 2006-05-03
CN1832745A (zh) 2006-09-13
MY136965A (en) 2008-12-31
NO20060553L (no) 2006-02-02
WO2005013988A1 (en) 2005-02-17
ES2222833A1 (es) 2005-02-01
MXPA06001140A (es) 2006-04-24
CN1829516A (zh) 2006-09-06
CA2534101A1 (en) 2005-02-17
US20070105853A1 (en) 2007-05-10
EP1651220B1 (en) 2006-12-20
JP2007500162A (ja) 2007-01-11
ES2222833B1 (es) 2006-03-01
DE602004003829T2 (de) 2007-09-20
PT1651220E (pt) 2007-03-30
TW200510379A (en) 2005-03-16
ATE348615T1 (de) 2007-01-15
US20110172270A1 (en) 2011-07-14
DE602004003829D1 (de) 2007-02-01
DE602004003831D1 (de) 2007-02-01
RU2006105711A (ru) 2007-09-20
JP2007500169A (ja) 2007-01-11
AU2004262482A1 (en) 2005-02-17
AU2004262491A1 (en) 2005-02-17
WO2005013990A1 (en) 2005-02-17
PT1648458E (pt) 2007-03-30
US20080119516A1 (en) 2008-05-22
PE20050332A1 (es) 2005-06-12
RU2006105792A (ru) 2007-09-20
ATE348614T1 (de) 2007-01-15
ES2279400T3 (es) 2007-08-16
EP1648458A1 (en) 2006-04-26
NO20060605L (no) 2006-02-07

Similar Documents

Publication Publication Date Title
BRPI0508514A (pt) aril piperidinas ou piperazinas substituìdas por heterociclos de 5-membros inibidoras de mtp
RU2489148C2 (ru) Ингибитор активации stat3/5
CY1124464T1 (el) Ενωση 1,2,4-οξαδιαζολο βενζοϊκου οξεος και χρηση αυτης για μη-νοηματικη καταστολη και τη θεραπεια ασθενειας
BRPI0718714B8 (pt) arilamidas substituídas por tiazol e oxazol, seu uso e composição farmacêutica que as compreende
BRPI0519769A2 (pt) compostos orgÂnicos
BRPI0409641A (pt) 1-4-diazepinas substituìdas e seu uso
BRPI0818006B8 (pt) compostos de piperidino-di-hidrotienopirimidinas substituídas, uso dos mesmos e formulações farmacêuticas
NZ614305A (en) Sulfonamide derivatives as bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
BRPI0410979A (pt) composto, composição farmacêutica, e, métodos para tratar uma doença em um animal mediada pela catepsina s e para tratar um paciente submetido a uma terapia
CY1108267T1 (el) Ενωσεις που επηρεαζουν τη γλυκοκιναση
BRPI0809655B8 (pt) uso de um composto e um agente terapêutico,composição farmacêutica,e,kit
BRPI0606644A2 (pt) derivados de 4-carboxamida tiazola
BRPI0415613A (pt) novos compostos de diazaspiroalcanos e seu uso no tratamento de doenças mediadas por ccr8
BRPI0412997A (pt) derivados de dióxido de tiazol-benzoisotiazol substituìdos, método para produzir os mesmos e seu uso
PE20080360A1 (es) Derivados 4-bencilftalazinona 2-sustituidos como antagonistas de histaminas h1 y h3
BR0313377A (pt) Bifenilcarnboxamidas substituìdas por n-aril piperidina como inibidores de secreção de apolipoproteìna b
BRPI0408744A (pt) 4-feniltetrahidroisoquinolinas substituìdas, processos para preparação das mesmas, seu uso como medicamento, bem como medicamento que contém as mesmas
BR0115936A (pt) 2-anilino-benzimidazóis substituìdos e sua aplicação como inibidores de nhe
NO20092005L (no) MTP-Inhiberende piperidin- eller piperazinsubstituerte tetrahydro-naftalen-1-karboksylsyreforbindelser
BR0312294A (pt) Arilcarbonil piperazinas e hteroarilcarbonilpiperazinas e o uso das mesmas para tratamento de doenças benignas e malignas
SV2004001294A (es) Derivados de acido acetico ref. lea 35699-sv
BRPI0516025A (pt) 4-(heteroaril-metil e heteroaril-metil substituìda)-imidazol-2-tionas que atuam como agonistas alfa2 adrenérgicos
BRPI0612219A2 (pt) macrociclos amida v antibacterianos
BR112012020060B8 (pt) uso de n-((1-((4-hidroxitetrahidro-2h-piran-4-il)metil)piperidin-4-il)metil)-3-isopropil-2-oxo-2,3-dihidro-1h-benzo[d]imidazol-1-carboxamida para tratar doença de alzheimer e demência
BRPI0606942A2 (pt) derivados de n-[(4,5-difenil-2-tienil)metil]amina, o respectivo processo e a respectiva aplicação em terapêutica

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2159 DE 22/05/2012.